Skip to main content

Table 3 *Empiric, first adequate and definitive antimicrobial choice and associated 30-day case-fatality

From: Clinical and microbiological characteristics of bloodstream infections due to AmpC β-lactamase producing Enterobacteriaceae: an active surveillance cohort in a large centralized Canadian region

Empiric antibiotic choice Case fatality rate First adequate antibiotic choice Case fatality rate Definitive antimicrobial therapy Case fatality rate
Antibiotics with activity against AmpC- producing Enterobacteriaceae      
Aminoglycoside 7/52 (13%) Aminoglycoside 10/80 (13%) Aminoglycoside 15/132 11%)
Beta-lactam/Beta-lactamase inhibitor combination 15/131 (11%) Beta-lactam/Beta-lactamase inhibitor combination 16/137 (12%) Beta-lactam/Beta-lactamase inhibitor combination 10/22 (45%)
Carbapenem 0/16 (0%) Carbapenem 3/31 (9.7%) Carbapenem 5/45 (11%)
Cefepime 1/3 (33%) Cefepime 1/5 (20%) Cefepime 1/4 (25%)
Cefoxitin 0/1 (0%) Cefixime 0/10 (0%) Cefotaxime 0/2 (0%)
Ceftazidime 1/15 (6.7%) Ceftazidime 0/10 (0%) Ceftazidime 0/1 (0%)
Ceftriaxone 11/85 (13%) Ceftriaxone 12/97 (12%) Ceftriaxone 1/7 (14%)
Cefuroxime 1/5 (20%) Colistin 0/1 (0%) Colistin 0/1 (0%)
Colistin 0/1 (0%) Fluoroquinolone 16/106 (15%) Fluoroquinolone 30/231 (13%)
Fluoroquinolone 10/76 (13%) TMP/SMX 0/9 (0%) TMP/SMX 0/14 (0%)
TMP/SMX 2/14 (14%)     
Antibiotics unlikely to have activity against AmpC- producing Enterobacteriaceae      
Ampicillin 3/30 (10%)     
Azithromycin 1/5 (20%)     
Cefazolin 5/39 (13%)     
Cephalexin 0/2 (0%)     
Clindamycin 0/4 (0%)     
Cloxacillin 2/7 (29%)     
Linezolid 0/1 (0%)     
Metronidazole 12/68 (18%)     
Penicillin 0/3 (0%)     
Rifampin 0/3 (0%)     
Vancomycin 6/37 (16%)     
  1. TMP/SMX = Trimethoprim/Sulfamethoxazole.
  2. *For each category the total number of episodes adds up to more than the actual number of episodes because some patients received multiple antibiotics corresponding to each time period.